title: In VitroActivities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread.
abstract: Treatments forClostridium difficileinfection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined thein vitrosusceptibilities of 199 prevalent or emergingClostridium difficilePCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity againstC. difficilewith no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance.
authors.affiliation: Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom Jane.freeman4@nhs.net.|Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Jane
authors.initials: J
authors.lastname: Freeman
authors.affiliation: Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Sally
authors.initials: S
authors.lastname: Pilling
authors.affiliation: Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Vernon
authors.affiliation: Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom.|Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Mark H
authors.initials: MH
authors.lastname: Wilcox
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000145:classification* / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004761:Enterocolitis, Pseudomembranous / Q000382:microbiology; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D023303:Oxazolidinones / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D011759:Pyrrolidines / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology*; D021521:Ribotyping
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C000622787:MCB3681; D023303:Oxazolidinones; D011759:Pyrrolidines; D015363:Quinolones; D000069349:Linezolid; D000077266:Moxifloxacin
keywords: Clostridium difficile; MCB3681; antimicrobial susceptibility